ReviewInternal and emergency medicine2026
Strategies for therapeutic optimization and proactive care in chronic obstructive pulmonary disease (COPD): an Italian expert opinion.
Review in Internal and emergency medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic obstructive pulmonary disease (COPD) remains a major public health challenge, characterized by substantial underdiagnosis, high morbidity and mortality, and significant healthcare burden. In Italy, the gap between estimated and diagnosed prevalence highlights the need for improved early detection and proactive management. This expert opinion, developed by a multidisciplinary panel, translates current evidence into practical recommendations tailored to the Italian healthcare context. Patient characterization has moved from a spirometry-centered approach to a proactive, multidimensional model integrating symptom burden, exacerbation history, and cardiopulmonary risk. Early diagnosis should be driven by structured case-finding in primary care and internal medicine, using spirometry for confirmation. Early identification of uncontrolled patients relies on standardized tools, including symptom quantification (CAAT score) and indirect markers like recurrent antibiotic or oral corticosteroid use. Exacerbations are critical events that accelerate both pulmonary and cardiovascular deterioration, identifying a high-risk phase requiring prompt reassessment and optimization. In this context, single-inhaler triple therapy (SITT) is the only pharmacological strategy consistently associated with reduced exacerbations and all-cause mortality in high-risk populations. Timely SITT use may also reduce cardiopulmonary risk. Furthermore, preventing exacerbations limits antibiotic and systemic corticosteroid use, promoting antimicrobial stewardship and mitigating resistance. This expert opinion emphasizes the need for integrated care pathways, standardized clinical tools, and multidisciplinary coordination to overcome therapeutic inertia. A shift toward early identification, timely intervention, and prevention-oriented strategies is essential to improve outcomes and reduce the systemic burden of COPD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.